S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
Log in

Titan Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TTNP)

$0.17
0.00 (0.00 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$0.17
Now: $0.17
$0.19
50-Day Range
$0.17
MA: $0.36
$0.48
52-Week Range
$0.16
Now: $0.17
$3.78
Volume9.88 million shs
Average Volume1.07 million shs
Market Capitalization$2.99 million
P/E RatioN/A
Dividend YieldN/A
Beta1.18
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TTNP
CUSIPN/A
Phone650-244-4990

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.62 million
Book Value$0.53 per share

Profitability

Net Income$-9,020,000.00
Net Margins-352.17%

Miscellaneous

Employees23
Market Cap$2.99 million
Next Earnings Date11/13/2019 (Estimated)
OptionableOptionable

Receive TTNP News and Ratings via Email

Sign-up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter.


Titan Pharmaceuticals (NASDAQ:TTNP) Frequently Asked Questions

What is Titan Pharmaceuticals' stock symbol?

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

When did Titan Pharmaceuticals' stock split? How did Titan Pharmaceuticals' stock split work?

Titan Pharmaceuticals's stock reverse split before market open on Friday, January 25th 2019. The 1-6 reverse split was announced on Thursday, January 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 24th 2019. An investor that had 100 shares of Titan Pharmaceuticals stock prior to the reverse split would have 17 shares after the split.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) released its quarterly earnings data on Wednesday, August, 14th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.21. The specialty pharmaceutical company earned $0.50 million during the quarter, compared to analysts' expectations of $1.30 million. Titan Pharmaceuticals had a negative return on equity of 412.65% and a negative net margin of 352.17%. View Titan Pharmaceuticals' Earnings History.

When is Titan Pharmaceuticals' next earnings date?

Titan Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Titan Pharmaceuticals.

What price target have analysts set for TTNP?

1 Wall Street analysts have issued 1-year price targets for Titan Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Titan Pharmaceuticals' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 2,188.3% from the stock's current price. View Analyst Price Targets for Titan Pharmaceuticals.

What is the consensus analysts' recommendation for Titan Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Titan Pharmaceuticals.

Has Titan Pharmaceuticals been receiving favorable news coverage?

Media stories about TTNP stock have trended somewhat negative on Friday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Titan Pharmaceuticals earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Titan Pharmaceuticals.

Who are some of Titan Pharmaceuticals' key competitors?

What other stocks do shareholders of Titan Pharmaceuticals own?

Who are Titan Pharmaceuticals' key executives?

Titan Pharmaceuticals' management team includes the folowing people:
  • Dr. Marc Rubin, Exec. Chairman (Age 64)
  • Mr. Sunil Bhonsle, Pres, CEO, Principal Financial Officer & Director (Age 69)
  • Dr. Katherine L. Beebe-DeVarney Ph.D., Exec. VP & Chief Scientific Officer (Age 58)
  • Mr. Dane D. Hallberg, Exec. VP & Chief Commercial Officer (Age 50)

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Titan Pharmaceuticals' stock price today?

One share of TTNP stock can currently be purchased for approximately $0.17.

How big of a company is Titan Pharmaceuticals?

Titan Pharmaceuticals has a market capitalization of $2.99 million and generates $6.62 million in revenue each year. The specialty pharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Titan Pharmaceuticals employs 23 workers across the globe.View Additional Information About Titan Pharmaceuticals.

What is Titan Pharmaceuticals' official website?

The official website for Titan Pharmaceuticals is http://www.titanpharm.com/.

How can I contact Titan Pharmaceuticals?

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SOUTH SAN FRANCISCO CA, 94080. The specialty pharmaceutical company can be reached via phone at 650-244-4990 or via email at [email protected]


MarketBeat Community Rating for Titan Pharmaceuticals (NASDAQ TTNP)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  267 (Vote Outperform)
Underperform Votes:  260 (Vote Underperform)
Total Votes:  527
MarketBeat's community ratings are surveys of what our community members think about Titan Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel